TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05766709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
Description: NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
Description: NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499/Semaglutide A (40/0.33mg/mL)
Description: NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
Study: NCT05593055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Study: NCT05806775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with blood flow restriction
Description: A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
Study: NCT05439668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic abdominal strengthening exercises
Description: Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal exercises program
Description: Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
Study: NCT05151471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral edaravone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral edaravone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT06495502

Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews by qualitative health researchers

Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews by qualitative health researchers

Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews by qualitative health researchers
Study: NCT04562987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Control
Description: Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
Study: NCT06335108

Intervention type: PROCEDURE
Intervention: General Anaesthesia
Description: Breast surgery is carried out under general anesthesia.

Intervention type: PROCEDURE
Intervention: Local tumescent anaesthesia
Description: Breast surgery is carried out under local tumescent anesthesia.
Study: NCT05681572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
Study: NCT05292950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-MUC5AC
Description: single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study: NCT06178341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kata Inhalations-App
Description: The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control).
Study: NCT06064851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volta System
Description: The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volta System
Description: The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
Study: NCT06643312

Intervention type: DEVICE
Group type: OTHER
Intervention: The Tethered Pelvic Assist Device (TPAD)
Description: a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.

Intervention type: DEVICE
Group type: OTHER
Intervention: The Tethered Pelvic Assist Device (TPAD)
Description: a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
Study: NCT05751434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
Study: NCT04956042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosciclopirox
Description: Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosciclopirox + Cytarabine
Description: Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle
Study: NCT02217826

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DG3173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Study: NCT05364268

Intervention type: DEVICE
Intervention: Diagnostic Test: Diagnostic Software as Medical Device
Description: AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
Study: NCT06145724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Sepsis Safety Bundle
Description: Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
Study: NCT06494384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Treatment as usual (PST as usual)
Description: PST is a skills-based intervention that teaches clients a 7-step approach in which they 1) select a specific problem and define it in concrete terms,2) select a goal that is feasible to reach before next session, 3) brainstorm various ways to accomplish the goal, 4) evaluate pros and cons of each solution, including the likelihood they can actually implement it, 5) select the best solution, 6) create a plan to implement the solution, and 7) evaluate the plan afterward to ascertain the effectiveness of the solution. Practitioners teach and illustrate the PST process to clients at each session and encourage clients to implement action plans developed using the PST process. Clients are also encouraged to practice the PST process with additional problems between sessions, in order to gain mastery over the PST skills, enhance behavioral activation and as a result improve their belief in their ability to solve problems on their own (self efficacy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment Aid (PST-Aid)
Description: PST-Aid is an internet-based tool to support the delivery of PST. PST-Aid incorporates decision support for the practitioner as well as client and provides PST treatment support functions (i.e., scaffolding), including patient problem lists and session worksheets. PST-Aid was designed to be used during remote sessions, such that practitioners and clients can interact throughout the session while collaboratively viewing and editing worksheets on their own browsers.This system was developed into a prototype that was piloted and found to be acceptable and with adequate usability.
Study: NCT04891341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Supported Task-Oriented Circuit Training
Description: Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~1. Sit to stand~2. Standing and trunk training~3. Standing and lower limb training~4. Stepping~5. Walking~6. Walking with object manipulation~7. Climbing and descending stairs~8. Unilateral upper extremity activity training (VR)~9. Bilateral upper extremity activity training (VR)~10. Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Telerehabilitation
Description: Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
Study: NCT05135026

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonograpgy
Description: 2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
Study: NCT05755945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Application
Description: Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache.
Study: NCT04939519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN)
Description: Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
Study: NCT06379048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Matress Suturing
Description: Horizontal matress suture in interrupted fashion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Suturing
Description: Horizontal primary suture in interrupted fashion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Subcutaneous Suturing
Description: Subcutaneous suture in continuous fashion
Study: NCT05506826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fine motor activities
Description: patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy and mirror therapy
Description: Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
Study: NCT06326892

Intervention type: PROCEDURE
Intervention: Natural Orifice Specimen Extraction (NOSE)
Description: Low rectal cancer resection with Total Mesorectal Excision (TME) and Natural Orifice Specimen Extraction (NOSE)

Intervention type: PROCEDURE
Intervention: Traditional specimen extraction
Description: Low rectal cancer resection with Total Mesorectal Excision (TME) and specimen extraction through Pfannenstiel incision
Study: NCT05446428

Intervention type: OTHER
Intervention: study of IFNGS expression biomarkers
Description: Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.

Intervention type: OTHER
Intervention: study of IFNGS expression biomarkers
Description: Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
Study: NCT05593874

Intervention type: DIAGNOSTIC_TEST
Intervention: Histones H3.1 blood levels
Description: Measure of blood concentrations of histone subtype H3.1
Study: NCT05731570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Description: Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
Study: NCT04795726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
Study: NCT06227273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen water
Description: Daily consumption of hydrogen water for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen water
Description: Daily consumption of hydrogen water for 16 weeks.
Study: NCT05823025

Intervention type: OTHER
Intervention: PWV measurement
Description: Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.

Intervention type: OTHER
Intervention: PWV measurement
Description: Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
Study: NCT05141162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: case and control group
Description: randomized controlled experimental study
Study: NCT05290688

Intervention type: GENETIC
Group type: OTHER
Intervention: 50 ml blodd sampling
Description: 50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
Study: NCT04858854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane, administered as Broccoli sprout extract
Description: Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sulforaphane, administered as Broccoli sprout extract
Description: Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
Study: NCT05644457

Intervention type: GENETIC
Intervention: Circulating tumour DNA dynamics
Description: Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.